中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2008年
4期
475-477
,共3页
邓在春%虞亦鸣%陈鲧%钟国平%谭云山%徐永华%白春学
鄧在春%虞亦鳴%陳鯀%鐘國平%譚雲山%徐永華%白春學
산재춘%우역명%진곤%종국평%담운산%서영화%백춘학
癌,非小细胞肺%血管内皮生长因子类%基因,erbB
癌,非小細胞肺%血管內皮生長因子類%基因,erbB
암,비소세포폐%혈관내피생장인자류%기인,erbB
Carcinoma,non-smal-cell lung%Vascular endothelial growth factors%Genes,erbB
目的 检测人类表皮生长因子受体4(HER4)及血管内皮生长因子(VEGF)在非小细胞肺癌(NSCLC)中的表达,探讨HER4、VEGF表达与NSCLC临床病理特征之间的联系.方法 用免疫组织化学方法 检测82例手术切除的NSCLC组织中HER4与VEGF的表达.结果 NSCLC中HER4的过度表达率为65.9%,VEGF的阳性表达率为53.7%.HER4、VEGF的表达与淋巴结转移和TNM分期有关,而与NSCLC病理类型和分化程度无关,且HER4与VEGF的表达有相关性.结论 HER4与VEGF可能是晚期肺癌生长的调控因子,针对HER4与VEGF的联合靶向治疗可能成为治疗晚期肺癌的有效方法 .
目的 檢測人類錶皮生長因子受體4(HER4)及血管內皮生長因子(VEGF)在非小細胞肺癌(NSCLC)中的錶達,探討HER4、VEGF錶達與NSCLC臨床病理特徵之間的聯繫.方法 用免疫組織化學方法 檢測82例手術切除的NSCLC組織中HER4與VEGF的錶達.結果 NSCLC中HER4的過度錶達率為65.9%,VEGF的暘性錶達率為53.7%.HER4、VEGF的錶達與淋巴結轉移和TNM分期有關,而與NSCLC病理類型和分化程度無關,且HER4與VEGF的錶達有相關性.結論 HER4與VEGF可能是晚期肺癌生長的調控因子,針對HER4與VEGF的聯閤靶嚮治療可能成為治療晚期肺癌的有效方法 .
목적 검측인류표피생장인자수체4(HER4)급혈관내피생장인자(VEGF)재비소세포폐암(NSCLC)중적표체,탐토HER4、VEGF표체여NSCLC림상병리특정지간적련계.방법 용면역조직화학방법 검측82례수술절제적NSCLC조직중HER4여VEGF적표체.결과 NSCLC중HER4적과도표체솔위65.9%,VEGF적양성표체솔위53.7%.HER4、VEGF적표체여림파결전이화TNM분기유관,이여NSCLC병리류형화분화정도무관,차HER4여VEGF적표체유상관성.결론 HER4여VEGF가능시만기폐암생장적조공인자,침대HER4여VEGF적연합파향치료가능성위치료만기폐암적유효방법 .
Objectives To explore the expression of HER4 and VEGF in NSCLC and elucidate the relationship between their expression and the characteristic of clinical pathology. Methods 82 cases of paraffin-embedded tissues from informative NSCLC were used to detect the expression of HER4 and VEGF by means of immunohistochemical assay. Results HER4 is overexpressed in 65;9%of NSCLC cases. The overexpression of HER4 is correlated with the lymph node metastasis and TNM staging. VEGF is expressed in 53.7%of NSCLC cases. The expression of VEGF is also correlated with the lymph node metastasis and TNM staging, and the expression of VEGF is correlated with the overexpression of HER4.Conclusions HER4 and VEGF are the protein to regulate the growth of NSCLC and it might be a good way for the treatment of NSCLC by suppressing the overexpression of HER4 and VEGF.